New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 22, 2014
09:30 EDTBSXBoston Scientific begins trial of ACUITY X4 LV pacing leads
Boston Scientific has conducted the first implant in the clinical trial of the next generation ACUITY X4 left-ventricular pacing leads and RELIANCE™ 4-FRONT defibrillation leads. The clinical trial is designed to establish the safety and effectiveness of both lead families and is intended to support U.S. Food and Drug Administration approval of these devices.
News For BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 28, 2015
11:52 EDTBSXBoston Scientific to pay $119M to resolve 2,970 product liability claims
Subscribe for More Information
11:25 EDTBSXBoston Scientific to host investor day
Subscribe for More Information
07:05 EDTBSXBoston Scientific sees Q2 adjusted EPS 20c-22c, consensus 22c
Subscribe for More Information
07:05 EDTBSXBoston Scientific backs FY15 adjusted EPS 88c-92c, consensus 91c
Cuts FY15 revenue to $7.23B-$7.38B from $7.3B-$7.5B, consensus $7.43B.
07:04 EDTBSXBoston Scientific reports Q1 Cardiovascular revenue up 10% to $712M
Reports Q1 Rhythm Management revenue up 4% to $514M; Reports Q1 MedSurg revenue up 4% to $542M.
07:02 EDTBSXBoston Scientific reports Q1 adjusted EPS 21c, consensus 21c
Reports Q1 revenue $1.77B, consensus $1.78B
05:51 EDTBSXBoston Scientific drug Eluvia trial meets primary endpoint
Subscribe for More Information
April 27, 2015
16:23 EDTBSXBoston Scientific announces strategic collaboration with Brainlab AG
Subscribe for More Information
15:04 EDTBSXNotable companies reporting before tomorrow's open
Subscribe for More Information
April 20, 2015
16:09 EDTBSXBoston Scientific announces long-term data underscore safety, efficacy of S-ICD
The Journal of the American College of Cardiology published data confirming the long-term safety and efficacy of the Boston Scientific S-ICD System for patients at risk of sudden cardiac arrest. The study, "Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-year Results from a Pooled Analysis of the IDE Study and EFFORTLESS Registry" was led by Dr. Martin Burke, professor of medicine at the University of Chicago. The analysis combined data from two large S-ICD studies to provide the most comprehensive look at S-ICD System patient outcomes to date. The all-cause mortality rate for the S-ICD patients was 1.6% per year, comparing favorably to observed mortality rates in similar TV-ICD studies. Currently, the S-ICD System is covered nationally by Medicare, Aetna, Cigna and others, and regionally by numerous private and Medicaid plans, providing coverage for approximately 170M individuals in the U.S. The S-ICD System has been commercially available in Europe since 2009.
07:44 EDTBSXSurvey shows strong momentum for Boston Scientific devices, says RBC Capital
RBC Capital says that its survey supports strong momentum for Boston Scientific's S-ICD and Watchman, and the firm thinks the company is probably gaining share in single-chamber ICDs. The firm raised its price target on the shares to $20 from $17 and recommends buying the shares at current levels or on pullbacks.
April 16, 2015
16:11 EDTBSXBoston Scientific enrolls first patient REDUCE-HTN: REINFORCE study
Boston Scientific announced the first patient in the REDUCE-HTN: REINFORCE study was enrolled this week at Cardiology P.C. at Princeton Baptist Medical Center in Birmingham, AL by Farrell Mendelsohn, M.D., site principal investigator, and referred by Michael Wilensky, M.D. Boston Scientific received an investigational device exemption, or IDE, for the study from the FDA in December.
April 14, 2015
09:09 EDTBSXBoston Scientific announces strategic alliance with Frankenman
Boston Scientific announced the signing of a strategic alliance with Frankenman Medical Equipment Company, a recognized leader with deep local market expertise in the China surgical devices market. This alliance is expected to enable Boston Scientific and Frankenman to reach more clinicians and treat more patients by providing access to training on less invasive endoscopic technologies and the clinical and economic benefits these therapies can provide. CPEChina Fund, an entity of CITIC PE, is a current shareholder of Frankenman and will continue to support the company's growth in alignment with this strategic partnership.Under the terms of the agreement, Boston Scientific will become a shareholder of Frankenman, and provide services and expertise to Frankenman to support its continued growth, development pipeline and manufacturing capabilities. The transaction is expected to close in the first half of 2015, subject to customary closing conditions.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use